Big data and AI services provider DataStory has secured 250 million yuan ($39 million) in a Series C+ round, while CDMO services specialist Yiming Cell Technology has raised nearly 200 million yuan ($30 million).
DataStory bags $39m in a Series C+ round
DataStory, a developer of big data and AI services and applications for enterprises, has secured 250 million yuan ($39 million) in a Series C+ round of financing, per a company statement on Thursday.
Xiaomi Corporation alongside its investment arm Shunwei Capital jointly led the fresh round.
Proceeds from the financing will be used to spruce up four projects — platform-as-a-service (PasS) based system, product innovations, business ecosystem development, and global expansion.
Six-year-old DataStory leverages its big data platform and cognitive AI technology to support digitalisation across industries. Through a matrix of five cloud computing products linking to content, sales, and marketing, it helps companies improve efficiency toward product innovation, brand marketing and service support.
DataStory has already closed six other rounds of financing and is backed by Zhuhai Da Heng Qin Company, Technology Financial Group, Ipsos Investment, and Join-Cheer Software, among others.
Yiming Cell raises nearly $30m in Series B round
Yiming Cell Technology Co., Ltd, a contract development manufacturing organisation (CDMO) for gene and cell therapy, announced on Thursday that it has pocketed approximately 200 million yuan ($30 million).
It attracted two new investors namely Addor Capital and IDG Capital, while existing investors including Huagai Capital, Cowin Capital, and healthcare industry-focused investment firm Ming Bioventures, re-upped in the current round, according to a company statement.
The fresh round follows the completion of 120 million yuan ($18.7 million) in a Series A round from Huagai Capital, Cowin Capital, Ming Ventures, and other investors late last year.
Yiming will invest the fund for CDMO solutions, facility base, marketing activity, and technology innovation.
Headquartered in Beijing, Yiming runs as a biotechnology company that provides one-stop drug discovery and development service for global pharmaceutical enterprises.